Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new treatment option lands in the guidelines for a tough-to-treat bile duct cancer. Lirafugratinib, an oral FGFR2 inhibitor, has been added to the NCCN Guidelines as a category 2A preferred subsequent-line therapy for cholangiocarcinoma with an FGFR2 fusion or rearrangement — just weeks after its FDA approval in September 2026. The move was backed by strong phase 1/2 ReFocus trial data showing a 46% response rate and nearly two-year median overall survival.
A new standard emerges for FGFR2-driven bile duct cancer
Lirafugratinib (Lyrfigtu) has been officially added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Biliary Tract Cancers as a category 2A preferred subsequent-line therapy for patients with cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement. The guideline update follows swiftly on the heels of the drug's FDA approval on September 23, 2026 — a sign of how compelling the clinical data were.
The approval and guideline inclusion are both grounded in results from the phase 1/2 ReFocus trial, which enrolled patients with previously treated, FGFR inhibitor–naive CCA. What sets lirafugratinib apart from existing FGFR inhibitors is its irreversible, highly selective mechanism targeting only FGFR2 — potentially enabling more durable receptor inhibition and a cleaner side-effect profile compared to pan-FGFR inhibitors. A European Medicines Agency (EMA) marketing authorization application has also been submitted, signaling global ambitions for the drug.
By the Numbers
Why it matters: Cholangiocarcinoma is a rare and aggressive cancer with limited second-line options. Lirafugratinib's rapid transition from FDA approval to NCCN guidelines gives oncologists a well-supported, guideline-backed choice for the subset of CCA patients whose tumors carry FGFR2 fusions or rearrangements — a biomarker-driven approach that could meaningfully improve outcomes.
